Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2009 1
2011 1
2013 1
2014 5
2015 6
2016 3
2017 8
2018 19
2019 17
2020 15
2021 16
Text availability
Article attribute
Article type
Publication date

Search Results

82 results
Results by year
Filters applied: . Clear all The following term was not found in PubMed: Dzhurinskiy
Page 1
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC; ELIXA Investigators. Pfeffer MA, et al. N Engl J Med. 2015 Dec 3;373(23):2247-57. doi: 10.1056/NEJMoa1509225. N Engl J Med. 2015. PMID: 26630143 Free article. Clinical Trial.
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
Motzer RJ, Nosov D, Eisen T, Bondarenko I, Lesovoy V, Lipatov O, Tomczak P, Lyulko O, Alyasova A, Harza M, Kogan M, Alekseev BY, Sternberg CN, Szczylik C, Cella D, Ivanescu C, Krivoshik A, Strahs A, Esteves B, Berkenblit A, Hutson TE. Motzer RJ, et al. J Clin Oncol. 2013 Oct 20;31(30):3791-9. doi: 10.1200/JCO.2012.47.4940. Epub 2013 Sep 9. J Clin Oncol. 2013. PMID: 24019545 Free PMC article. Clinical Trial.
The final overall survival (OS) analysis showed a trend toward longer survival on the sorafenib arm than on the tivozanib arm (median, 29.3 v 28.8 months; HR, 1.245; 95% CI, 0.954 to 1.624; P = .105). Adverse events (AEs) more common with tivozanib than with sorafenib were …
The final overall survival (OS) analysis showed a trend toward longer survival on the sorafenib arm than on the tivozanib arm (median, 29.3 …
Synthesis of (Het)aryl 2-(2-hydroxyaryl)cyclopropyl Ketones.
Fadeev AA, Chagarovskiy AO, Makarov AS, Levina II, Ivanova OA, Uchuskin MG, Trushkov IV. Fadeev AA, et al. Molecules. 2020 Dec 5;25(23):5748. doi: 10.3390/molecules25235748. Molecules. 2020. PMID: 33291488 Free PMC article.
[Our first experience with endoscopic ear surgery].
Grachev NS, Polev GA, Morozov II, Samarin AE, Vorozhtsov IN, Shcherbakov DA. Grachev NS, et al. Vestn Otorinolaringol. 2020;85(1):88-93. doi: 10.17116/otorino20208501188. Vestn Otorinolaringol. 2020. PMID: 32241997 Russian.
MATERIAL AND METHODS: From March 2017 to November 2019 in NSRC PHOI named after Dmitry Rogachev in the Department of Oncology and Pediatric Surgery 53 patients (81 surgeries) have undergone endoscopic-assisted ear surgery: 3 biopsies for middle ear neoplasm with the transc …
MATERIAL AND METHODS: From March 2017 to November 2019 in NSRC PHOI named after Dmitry Rogachev in the Department of Oncology and Ped …
[Balloon sinuplasty in children - Russian first experience].
Zyabkin IV, Grachev NS, Karpova EP, Vorozhtsov IN, Yaremenko EY. Zyabkin IV, et al. Vestn Otorinolaringol. 2020;85(1):48-53. doi: 10.17116/otorino20208501148. Vestn Otorinolaringol. 2020. PMID: 32241989 Russian.
Flow cytometry for pediatric platelets.
Ignatova AA, Ponomarenko EA, Polokhov DM, Suntsova EV, Zharkov PA, Fedorova DV, Balashova EN, Rudneva AE, Ptushkin VV, Nikitin EA, Shcherbina A, Maschan AA, Novichkova GA, Panteleev MA. Ignatova AA, et al. Platelets. 2019;30(4):428-437. doi: 10.1080/09537104.2018.1513473. Epub 2018 Oct 4. Platelets. 2019. PMID: 30285517
The method output includes levels of forward and side scatter, levels of major adhesion and aggregation glycoproteins Ib and IIb-IIIa, active integrins' level based on PAC-1 binding, major alpha-granule component P-selectin, dense granule function based on mepacrine uptake and re …
The method output includes levels of forward and side scatter, levels of major adhesion and aggregation glycoproteins Ib and IIb-IIIa, activ …
82 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page